Member Info for HarChris

Peter Horby will be offering patients money NOT to join our trial.

It was the 95% figure that caused the shock, totally unexpected and turned everything on its head. If you register the gravity of the news in the moment you are going to hedge your bets, sell and watch what happens. If nothing moves buy back and take the small hit.

No declared shorts above 0.5% but you never know what's going on at the murky depths below.

Saw this on the novacyt bb and made me laugh:

Those that paid 10 or 11 quid I doubt very much those highs will be achieved again imo, downward trend is now gathering pace. What happened to pmjh.... Sold out I guess

So many theories he's left in his wake, even from companies he's never been near!

Last chance to get early bird prices, will be £3 on the door if there's any left or a fiver off the touts if not!

I get the sense there isn't much powder dry amongst this forum, we're all ALL IN!

We are going to need much more detail if we're to appoint you Head of Research in pmjh's absence.

Little old Synairgen rubbing shoulders with the biggest and brightest all the way back in 2012!
According to the table of contents, the report identifies the following companies as “key companies”: 3M, Akela, Alexza, Alkermes, AlphaRx, AOP Orphan Pharmaceuticals, APT Pharmaceuticals, Aradigm, AstraZeneca, Axentis Pharma, Consort Medical [Bespak], Daiichi Sankyo, Dey, Gilead, GSK, Graceway Pharmaceuticals [recently purchased by Galderma], Hovione, Inspire [acquired by Merck], MannKind Corporation, MAP Pharmaceuticals, Merck, MicroDose Therapeutx, MPEX, Nektar, Next Safety, Novartis, Oriel, Pearl, Pharmaxis, Pulmatrix, Respirics, Savara, SkyePharma, Sunovion, Synairgen, Teva, Theravance, United Therapeutics, and Vectura.

Fomo of what Big? I'm hoping IIs are using this time to build a stake and that perhaps drives the share price north. Beyond that we must be a good few weeks away from any fomo?

Have you changed your opinion on Activ 2 ever so slightly Doc?

What from oral to rectal?

For what we are hoping is a revolutionary treatment it's a bit frustrating/concerning that no one's taking it up (as far as we know) through MAP isn't it?

Soder I'm with you. I can't see the value at selling at the price people will be selling at though. Cash in the bank is good and growing by the day and there is a real opportunity of developing into a midcap company down the road. Will go long now and put my faith in the mgmt.

It needed clearer forward guidance, can't forever say 'revenue is expected for a little longer'

Most giving it the 'wow' are being a little disingenuous, we hoped (not expected) more. However at £750m mcap some are going to get burnt if they dump at £10 on open...

If only the extension of the DHSC contract was confirmed, that would have made the world of difference.

When you look at the vaccine war going on right now I don't think it would be a problem for sng if efficacy was 100%!

Was this the unicef deal we saw yesterday?

A little quieter on the findings for the SA variant...

A little birdie told me has has at least 5 more shares than pmjh.